Article
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.
Communications biology - 23 Feb 2022
Li Li, Li Zhujun, Lu Conghua, Li Jianghua, Zhang Kejun, Lin Caiyu, Tang Xiaolin, Liu Zhulin, Zhang Yimin, Han Rui, Wang Yubo, Feng Mingxia, Zhuang Yuan, Hu Chen, He Yong
Abstract excerpt
Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer (NSCLC) patients, while acquired drug resistance will inevitably occur. Interleukin-6 (IL-6) is a keystone cytokine in inflammation and cancer, while its role in osimertinib efficacy was unknown. Here we show that clinically, plasma IL-6...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.